menu
    • menu
    [{"orgOrder":0,"company":"ME Therapeutics","sponsor":"NanoVation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ME Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ME Therapeutics \/ NanoVation Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"ME Therapeutics \/ NanoVation Therapeutics"},{"orgOrder":0,"company":"ME Therapeutics","sponsor":"ME Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Licensing Agreement","leadProduct":"CLIC-2201","moa":"CD22","graph1":"Oncology","graph2":"Phase I","graph3":"ME Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ME Therapeutics \/ ME Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"ME Therapeutics \/ ME Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by ME Therapeutics

    Menu

    ME Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ME Therapeutics

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ME Therapeutics

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLIC-2201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : National Research Council of Canada

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Me Therapeutics Licenced CD22 Nanobody to Expand CAR Cell Therapy Program

                            Details : Through the licensing deal for CLIC-2201, targeting CD22, the agreement aims to advance cell & gene therapy for B-cell cancers.

                            Product Name : CLIC-2201

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            October 16, 2025

                            Lead Product(s) : CLIC-2201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : National Research Council of Canada

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ME Therapeutics

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ME Therapeutics

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : NanoVation Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ME Therapeutics Begins Testing mRNA Formulations with NanoVation Therapeutics

                            Details : The collaboration aims to enhance the precision and efficacy of mRNA therapeutics to develop potential new cancer therapies by leveraging the cutting-edge LNP technologies of NanoVation.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 20, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : NanoVation Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth